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A B S T R A C T
Background
Inappropriate activation of the renin–angiotensin system may play a part in the development
of preeclampsia. An insertion/deletion polymorphism within the angiotensin-I converting
enzyme gene (ACE-I/D) has shown to be reliably associated with differences in angiotensin-
converting enzyme (ACE) activity. However, previous studies of the ACE-I/D variant and
preeclampsia have been individually underpowered to detect plausible genotypic risks.
Methods and Findings
A prospective case-control study was conducted in 1,711 unrelated young pregnant women
(665 preeclamptic and 1,046 healthy pregnant controls) recruited from five Colombian cities.
Maternal blood was obtained to genotype for the ACE-I/D polymorphism. Crude and adjusted
odds ratio (OR) and 95% confidence interval (CI) using logistic regression models were obtained
to evaluate the strength of the association between ACE-I/D variant and preeclampsia risk. A
meta-analysis was then undertaken of all published studies to February 2006 evaluating the
ACE-I/D variant in preeclampsia. An additive model (per-D-allele) revealed a null association
between the ACE-I/D variant and preeclampsia risk (crude OR¼ 0.95 [95% CI, 0.81–1.10]) in the
new case-control study. Similar results were obtained after adjusting for confounders (adjusted
per-allele OR¼0.90 [95% CI, 0.77–1.06]) and using other genetic models of inheritance. A meta-
analysis (2,596 cases and 3,828 controls from 22 studies) showed a per-allele OR of 1.26 (95% CI,
1.07–1.49). An analysis stratified by study size showed an attenuated OR toward the null as
study size increased.
Conclusions
It is highly likely that the observed small nominal increase in risk of preeclampsia associated
with the ACE D-allele is due to small-study bias, similar to that observed in cardiovascular
disease. Reliable assessment of the origins of preeclampsia using a genetic approach may
require the establishment of a collaborating consortium to generate a dataset of adequate size.
The Editors’ Summary of this article follows the references.
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Introduction
Preeclampsia is a maternal disease of pregnancy associated
with increased blood pressure and proteinuria after 20 weeks
of gestation. It is a major cause of maternal and neonatal
mortality and morbidity worldwide and has particularly high
incidence in Latin American and Caribbean countries, in
which hypertensive disorders during pregnancy account for
25.7% of maternal deaths [1,2]. Preeclampsia is thought to be
the result of the interplay between important genetic
components and environmental inﬂuences; however, the
factors and the mechanisms that lead to preeclampsia remain
elusive [3]. As a result, there is a lack of effective preventive
interventions [4].
With the exception of smoking, established risk factors for
cardiovascular disease, including high blood pressure, dia-
betes, and obesity, are also risk factors for preeclampsia [5]. In
addition, women who suffer from preeclampsia have an
increased risk of later cardiovascular disease, which clearly
suggests a shared aetiology [6].
Inappropriate activation of the renin–angiotensin system
may play a part in the development of many cardiovascular
disorders, including preeclampsia [7,8]. A common insertion/
deletion polymorphism within the angiotensin-I converting
enzyme gene (ACE-I/D) has been reliably associated with
substantial differences in the plasma and tissue angiotensin-
converting enzyme (ACE) activity in a codominant (additive)
fashion not only in persons of European descent, but also in
other populations such as Hispanics [9–11]. Individuals
carrying the D allele have higher ACE activity, which has
been proposed as an intermediate phenotype of potential
relevance for the development of high blood pressure and
subclinical atheroma (i.e., higher intima-media thickness of
the carotid artery) [10,12]. Despite the biological plausibility
and the consistency of the effect of the ACE-I/D poly-
morphism on ACE activity, associations of the ACE-I/D
polymorphism and coronary heart disease, coronary artery
restenosis, stroke, and renal disease have been inconsistent
[13–16]. Moreover, systematic reviews and meta-analyses have
indicated the presence of small-study bias in the published
literature [13–16].
Several studies, also usually small in size, have reported
that women carrying the D allele of the ACE-I/D poly-
morphism have higher ACE activity and higher measures of
uterine artery resistance, which is a marker for develop-
ment of intrauterine growth retardation and preeclampsia
[8,17]. These observations led to the proposal that the ACE-
I/D polymorphism may be a good candidate in the search
for a cause of preeclampsia. However, to date, studies
evaluating the role of ACE-I/D polymorphism in preeclamp-
sia have been individually underpowered to detect plau-
sible genetic effect sizes, being much smaller than more
recent studies in cardiovascular disease. We hypothesized
that the published literature on the ACE-I/D polymorphism
in preeclampsia might be similarly affected by small-study
bias. To test this hypothesis, we conducted a new large
genetic association study on the ACE-I/D polymorphism and
preeclampsia in a geographical region with a high
incidence of preeclampsia. We then set this study within
the context of a systematic review and a meta-analysis of all
studies conducted to date.
Methods
Case-Control Study Participants
A prospective case-control study was conducted in 1,711
unrelated young pregnant women (665 preeclamptic partic-
ipants and 1,046 healthy pregnant controls) recruited from
ﬁve Colombian cities at the time of delivery between January
2000 and December 2005. A verbal interview with a
structured questionnaire was conducted by trained personnel
at the time of the delivery to ascertain maternal age,
gestational age, parity, smoking status during pregnancy,
family history of preeclampsia, ethnic background, and
socioeconomic position. On two separate occasions, the
mean of two readings of blood pressure was obtained (four
measurements in total) at the time of delivery. Blood pressure
was measured in the right arm after a ﬁve-minute period of
rest in a seated position using mercury sphygmomanometers
or electronic devices calibrated against a mercury standard.
A case was deﬁned as a primigravid woman younger than
26 years old with blood pressure 140/90 mm Hg or above, and
proteinuria 0.3 grams or above in 24 hours, or a reading 2þor
above on a dipstick in a random urine determination with no
evidence of urinary tract infection after 20 weeks of gestation
[18]. At least one control was recruited after each case within
a window of 24 hours from the same hospital that provided
the cases. A control was deﬁned as a primigravid woman
younger than 26 years old without preeclampsia and in
labour after 37 weeks of pregnancy. To improve the
homogeneity of the phenotype under evaluation, women
with a prior history of autoimmune, metabolic (including
diabetes or gestational diabetes), renal, or cardiac (including
chronic hypertension) diseases were excluded from the study.
All participants signed the informed consent document
approved by the Ethics Committee from the Universidad
Auto´noma de Bucaramanga, Colombia.
DNA extraction and genotyping. Blood was drawn from the
antecubital vein into EDTA and samples stored at50 8C for
DNA extraction, using the QIAamp DNA blood mini-kit
(QIAGEN, Hilden, Germany). The ACE-I/D polymorphism in
intron 16 was detected according to the method described by
Rigat, et al. [9]. PCR is known to have a tendency to
preferentially amplify the short deletion (D) allele in contrast
to the larger insertion (I) allele in a competitive ampliﬁcation
reaction when both alleles are present, as occurs in
individuals with the ID genotype. This leads to mistyping of
ID individuals as DD in approximately 4%–5% of the samples.
To avoid any mistyping of ID as DD, a second PCR
ampliﬁcation using insertion-speciﬁc primers was conducted
for all participants who were homozygous for the D allele [19].
For a detailed description of the genotyping methods, see
Protocol S1. All available DNA samples were genotyped and
included in the present report, with no exclusions. For quality
control, a random sample (n¼ 156) was subjected to a second
PCR and genotyping to minimize any possible misclassiﬁca-
tion. The Cohen’s kappa value among the samples regeno-
typed was equal to 0.95 (95% CI [conﬁdence interval], 0.94–
0.96), and the error rate was 2.56% (95% CI, 0.70–6.43).
Genotyping was conducted blinded to the clinical status of
the participants.
Statistical analysis. To evaluate the presence of differences
between groups, unpaired Student’s t-, v2, or Mann-Whitney
tests were used as appropriate. A test for departure from
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Hardy-Weinberg equilibrium was performed by v2 analysis.
The principal a priori hypothesis was that the association
between the ACE-I/D polymorphism and preeclampsia follows
an additive model according to the number of D alleles. The
additive ‘‘per-allele’’ model (in a log-scale) was based on the
effect of the ACE-I/D variant on its intermediate phenotype
(ACE activity), established in large studies and overviews as
being a reliable association [10]. However, recessive and
dominant models and multiple pairwise comparisons (ID
versus II and DD versus II) were also evaluated for complete-
ness as secondary outcomes.
Multivariate analysis using logistic regression methods was
also conducted to control for potential confounders (mater-
nal age, ethnic background, place of birth of the women,
recruitment centre, socioeconomic position, urinary or
vaginal infections during pregnancy, and smoking status
during pregnancy).
To explore the prior hypothesis that the genotypic odds
ratio (OR) is greater in women with an enriched phenotype,
an analysis using an additive model was repeated for women
stratiﬁed according to the presence of family history of
preeclampsia (positive versus negative family history in
mother or sisters), and disease severity with severe pree-
clampsia being deﬁned as blood pressure above 160/110 mm
Hg or proteinuria of 5 grams or more in 24 hours, eclampsia,
or the HELLP syndrome. For these analyses 99% CIs were
used to make some allowance for their exploratory nature. All
statistical analyses were conducted using Stata, Version 9
(Stata Corporation, College Station, Texas, United States).
Meta-Analysis
Search strategy and selection criteria. Electronic databases
(MEDLINE, EMBASE, LILACS, KoreaMed, and Google Schol-
ar) were searched up to February 2006 for all genetic
association studies evaluating the ACE-I/D polymorphism
and preeclampsia in humans in all languages. The search
strategy contained both medical subject heading terms and
text words as follows: ‘‘angiotensin-converting enzyme’’ or
‘‘ACE’’ or ‘‘peptidyl-dipeptidase A,’’ in combination with
‘‘pre-eclampsia’’ or ‘‘preeclampsia’’ or ‘‘pregnant hyper-
tensive disorders’’ or ‘‘pregnancy hypertension,’’ and com-
bined with ‘‘genetic’’ or ‘‘polymorphism(s)’’ or ‘‘mutation’’ or
‘‘genotype’’ or ‘‘gene(s).’’ No limits were used in the search
strategy. We searched for any additional studies in the
references of all identiﬁed publications, including previous
relevant meta-analyses, and used the MEDLINE option
‘‘related articles’’ for all the relevant papers.
For inclusion, studies had to involve unrelated women and
examine the association between the ACE-I/D polymorphism
and preeclampsia. Studies published as full-length articles or
letters in peer-reviewed journals in any language were
included, as well as abstracts taken from reference lists of
identiﬁed publications. Authors were contacted (on at least
three occasions) to obtain information on the genotype
frequency by case-control status and by disease severity
(severe and nonsevere preeclampsia), the use of blinding of
genotyping staff to clinical status, the deﬁnition of outcomes,
and, in a few cases, to clarify possible overlapping of study
results. A positive reply was obtained in 15 out of 21 study
authors contacted.
Data extraction. The following information was extracted
(entered into databases by two of the authors, JPC and MCP)
from each study and disagreements resolved by consensus:
year of publication, total cases, total controls, number of
individuals by each genotype, study design, source of controls,
matching variable, thresholds used to deﬁne preeclampsia,
country of origin, ethnicity, v2 goodness of ﬁt for Hardy-
Weinberg equilibrium and its p-value, use of blinding, mean
age of participants, frequency of nulliparous women, and
main exclusion criteria. In the few instances in which
genotype frequencies provided by the investigators in tabular
data differed slightly from published ﬁgures, the tabular data
Table 1. Maternal and Neonatal Characteristics of the Sample Studied
Category Variable Cases (n ¼ 665) Controls (n ¼ 1,046) p-Value
Ethnic background European descent 63 (9.5%) 141 (13.5%)
African American 117 (17.6%) 176 (16.3%)
Native American 9 (1.4%) 11 (1.1%)
Mixture 476 (71.6%) 718 (68.6%) 0.092
Socioeconomic Low socioeconomic status 585/642 (91.1%) 922/1,011 (91.2%) 0.958
Maternal Maternal age (y) 19.0 6 2.9 18.7 6 2.6 0.013
Smoking during pregnancy 11/660 (1.7%) 37/1,045 (3.5%) 0.023
Systolic blood pressure (mm Hg) 146.1 6 12.1 110.9 6 9.2 , 0.001
Diastolic blood pressure (mm Hg) 96.5 6 8.1 68.1 6 7.1 , 0.001
Multiple pregnancy 19/663 (2.9%) 4/1,038 (0.4%) , 0.001
Gestational age at delivery (wk) 37.0 6 3.6 39.2 6 1.2 , 0.001
Maternal ACE-I/D genotype DD 140 (21.1%) 230 (22.0%)
ID 382 (57.4%) 607 (58.0%) 0.72
II 143 (21.5%) 209 (20.0%)
Allele frequency D 662 (49.8%) 1,067 (51.0%)
I 668 (50.2%) 1,025 (49.0%) 0.483
Newborn characteristics Newborn weight (g) 2,626 6 730 3,126 6 434 , 0.001
Newborn height (cm) 46.9 6 4.6 49.6 6 2.4 , 0.001
Low (, 7) Apgar score at first min 83/671 (12.4%) 67/1,025 (6.5%) , 0.001
Low (, 7) Apgar score at fifth min 34/671 (5.1%) 5/1,024 (0.5%) , 0.001
Data are presented as n (%) or mean 6 SD.
doi:10.1371/journal.pmed.0030520.t001
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were used. Women with gestational hypertension were
excluded from the present meta-analysis in order to improve
the homogeneity of phenotype between studies.
Statistical analysis. Data were analysed using Stata 9. The
genetic model to be considered as the priori hypothesis was
an additive model, following the considerations previously
described for the case-control study. Secondary analyses
involved ORs for other genetic models of inheritance such as
recessive, dominant, and pairwise comparisons of the differ-
ent genotypes. For all the models used, the D allele was
considered the one at risk. For the additive or per-allele
model, the OR was compared between cases and controls by
assigning scores for different genotype groups and calculat-
ing ORs by logistic regression. We calculated the random
effect summary OR and CIs for each polymorphism. To make
some allowance for multiple comparisons 99% CIs were used
for individual studies, and 95% CIs were reserved for the
combined estimates. The inverse variance-weighted method
was used to calculate the summary OR [20]. Heterogeneity
was assessed by the DerSimonian and Laird Q test and I2 was
used as a measure to describe the percentage of variability in
point estimates that was due to heterogeneity rather than
sampling error [20]. Sources of between-study heterogeneity
were explored using random effect metaregression models
with restricted maximum likelihood estimation. The prespe-
ciﬁed characteristics for assessment of sources of inter-study
heterogeneity were: Study size (number of cases: ,100, 100–
200, and 200); blinding of genotyping staff (blinded,
unblinded, or unknown); disease severity (severe versus
nonsevere preeclampsia); ethnicity of women evaluated (of
European descent, Asian, Hispanic, Afro-Caribbean, and
others); preeclampsia deﬁnition (adequate versus unclear);
and publication language (English– versus non-English–
language journals). Funnel plots of the effect estimate against
the sample size, Egger regression asymmetry test, and a
weighted (by the inverse of the variance of the estimate)
linear ﬁxed regression of the log OR against the inverse of the
sample size (linear-regression model) were used to evaluate
small-study effects [20,21]. To evaluate stability over time of
the effect estimate, cumulative meta-analysis using random
effect models was conducted [20].
Results
Case-Control Study
Clinical and demographic data of the cases and controls
are shown in Table 1. There were no signiﬁcant differences in
maternal age, ethnic background, and socioeconomic posi-
tion between cases and controls (Table 1). Expected differ-
ences in maternal blood pressure, parity, and newborn weight
and condition were recorded.
The distribution of the ACE-I/D genotypes and allelic
frequencies were not signiﬁcantly different according to the
case-control status (Table 1). Genotype frequencies according
to the ethnic group and by recruitment centre are reported
in ‘‘Appendix Table I’’ in Protocol S1. An additive model
(per-D-allele) revealed a null association between the ACE-I/D
variant and preeclampsia risk (crude OR ¼ 0.95 [95% CI,
0.81–1.10]). Adjusting for maternal age, ethnicity, recruitment
centre, and place of birth, aimed to minimize the effect of
possible population admixture, did not change the estimate
of the effect (model-1 OR ¼ 0.92 [95% CI, 0.78–1.07]). A
similar result was obtained after further adjustment for
additional potential confounders such as socioeconomic
position, presence of urinary or vaginal infections during
pregnancy, and smoking status during pregnancy (model-2
OR¼ 0.90 [95% CI, 0.77–1.06]). ORs for other genetic models
of inheritance also yielded a null association (Table 2). Pre-
speciﬁed exploratory subgroup analyses indicated that with
the exception of family history of preeclampsia (positive-
history OR¼ 1.30 [99% CI, 0.75–2.26] versus negative-history
OR ¼ 0.86 [99% CI, 0.68–1.10]; p-value for heterogeneity
equal to 0.07), no substantial heterogeneity of the genetic
effect size was observed for any of the subgroups (Figure 1).
Additionally, stratiﬁed analysis by recruitment centre accord-
ing to the conformity with Hardy-Weinberg equilibrium
yielded similar, null results (see ‘‘Appendix Table II’’ in
Protocol S1).
Meta-Analysis
A total of 30 genetic association studies, including the
present study, evaluating the ACE-I/D gene variant and
preeclampsia risk were identiﬁed [17,22–49]. We excluded
eight out of 30 studies for one or more of the following
reasons: two in which duplication or partial overlapping of
reported data were considered likely [43,44]; three in which
the outcome evaluated was solely gestational hypertension
[45–47]; one in which relevant data were not reported and
could not be obtained from study authors [48]; one that only
recruited women with previous preeclampsia [17]; and one in
which the sampling frame was based on the ACE-I/D genotype
[49]. A total of 22 genetic association studies including 2,596
cases and 3,828 controls were included in the present meta-
analysis (Tables 3 and 4) [22–42]. Out of the 22 studies, nine
were conducted with Asian participants, eight with partic-
Table 2. Estimate of the Effect of the ACE-I/D Polymorphism on Preeclampsia Risk Modeled with Logistic Regression
Association Unadjusted OR (95% CI) Model-1 OR (95% CI) Model-2 OR (95% CI)
Dominant model (D-carriersa versus II) 0.91 (0.71–1.17) 0.86 (0.67–1.11) 0.84 (0.65–1.09)
Recessive model (DDa versus I-carriers) 0.95 (0.75–1.21) 0.93 (0.72–1.18) 0.92 (0.71–1.18)
Additive model (per- in increase in D-allelea) 0.95 (0.81–1.10) 0.92 (0.78–1.07) 0.90 (0.77–1.06)
Pairwise comparisons, IDa versus II 0.83 (0.65–1.06) 0.87 (0.67–1.13) 0.85 (10.65–1.12)
Pairwise comparisons, DDa versus II 0.81 (0.60–1.08) 0.83 (0.60–1.16) 0.82 (0.59–1.14)
Model-1: Adjusted by maternal age, ethnicity, recruitment centre, and place of birth. Model-2: Previous variables plus socioeconomic status, infections during pregnancy (urinary or
vaginal), and smoking status during pregnancy.
aThe genotype or allele considered at risk.
doi:10.1371/journal.pmed.0030520.t002
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ipants of European descent, two with African Americans, two
with more than one ethnic group, and one with South Asians.
The OR under an additive model for preeclampsia was 1.26
(95% CI, 1.07–1.49; p¼ 0.006) (Figure 2). However, there was
evidence of substantial between-study heterogeneity (I2 ¼
75.1%, v21
2¼ 84.23, pHet , 0.0001). Study characteristics such
as blinding of genotyping staff, publication language,
preeclampsia deﬁnition, and disease severity explained little
of the heterogeneity (Figure 3). A stratiﬁed analysis by study
size, evaluated as the number of cases in each study (,100,
100–200, and 200), showed a diminished effect as the study
size increased (v2
2 ¼ 16.95, pHet ¼ 0.0002) (Figure 3).
Analogous results were obtained when different cutoff points
(, 100, 100–500, and  500) for the number of cases were
used (v2
2 ¼ 18.51, pHet ¼ 0.00009). Similarly, stratifying by
ethnicity indicated that studies conducted in Asian popula-
tions tended to have a larger ORs (v5
2 ¼ 14.4, pHet ¼ 0.007).
These ﬁndings might be explained by the fact that eight out
of the nine studies conducted in Asian populations had fewer
than 100 cases in each study. The funnel plot including all
studies was asymmetric, and the Egger’s test (p¼ 0.06) and the
linear regression model (p¼ 0.003) suggested the presence of
an excess of small studies with more positive results,
predominately of studies published in non-English–language
journals (Figure S1; see Protocol S1 for details). A cumulative
synthesis of ACE-I/D variants and preeclampsia revealed
substantial instability of the genetic effect over time, with
studies published between 1996 and 1997 demonstrating the
most protective effect, immediately followed by studies
published in 1998 and 1999 indicating the most signiﬁcant
results in the opposite direction. Then, the effect size is seen
to attenuate gradually over time toward a null association
with the accumulation of more data (Figure S2; see Protocol
S1 for details). Genotypic ORs under other genetic models of
inheritance are outlined in Table 5.
Discussion
The current meta-analysis, which includes new data from
the largest case-control study to date, represents the most
comprehensive evaluation of the ACE-I/D variant in pree-
clampsia. Although a pooled per-allele OR suggested evi-
dence of an increase in the risk of preeclampsia of 1.26 (95%
CI, 1.07–1.49), the robustness of this summary estimate is
uncertain. First, our study found a null association of the
ACE-I/D variant with preeclampsia. Moreover, there was no
substantial evidence of a positive effect in any of the
subgroups in the prespeciﬁed analyses. Second, the meta-
analysis revealed diminishing summary risk estimate as study
size increased (Figure 3), regardless of the arbitrary cutoff
points used to deﬁne the categories. This result is concordant
with the results of several statistical tests used to evaluate the
presence of small-study bias (Egger’s test p¼ 0.06 and linear-
regression model test p¼ 0.003). Furthermore, since only the
published literature was included, it is possible that including
unpublished studies (which more often provide evidence of
negative or null effects) would have provided additional
evidence of small-study bias. Taken together, these ﬁndings
point to small-study bias as a potential explanation for the
results observed in the meta-analysis. Discrepant ﬁndings
from large and small studies are not new in the ﬁeld of
genetics of complex disorders [50]. When present, discrep-
ancy of genetic effects sizes may be due to multiple causes
such as genuine heterogeneity, data manipulation and
fabrication, study quality, or publication bias. A form of
publication bias relevant to the current report is within-study
reporting bias. Because of the facility of measuring multiple
genetic markers in a study, signiﬁcant positive and negative
associations (sometimes arising from multiple testing) are
more likely to be published early rather than late. Results
from the cumulative meta-analysis support this as one
possible explanation, which has been referred to as the
Figure 1. Risk Association of ACE-I/D Variant with Preeclampsia in Selected Subgroups within the Current Study
doi:10.1371/journal.pmed.0030520.g001
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Table 3. Characteristics of Published Studies of the Association between the ACE-I/D Polymorphism and Preeclampsia Included in the
Meta-Analysis
Reference Year Total
Cases
Total
Controls
Total
Sample
Size
DD
Genotype
Cases, n
ID
Genotype
Cases, n
II
Genotype
Cases, n
DD
Genotype
Controls, n
ID
Genotype
Controls, n
II
Genotype
Controls, n
Design
Bai [22] 2002 81 199 280 8 38 35 31 83 85 Case-control
Bouba [23] 2003 41 102 143 17 19 5 29 52 21 Case-control
Choi H [24] 2004 90 98 188 33 34 23 14 51 33 Case-control
Dizon-Townson [25] 1995 124 200 324 49 42 33 65 98 37 Case-control
Galao [26] 2004 51 71 122 16 23 12 21 33 17 Case-control
Gurdol [27] 2004 95 89 184 47 31 17 31 37 21 Case-control
Heiskanen [28] 2001 133 115 248 43 59 31 31 58 26 Case-control
Kaur [29] 2005 50 50 100 30 14 6 15 26 9 Case-control
Kim [30] 2004 98 110 208 26 36 36 25 52 33 Case-control
Kobashi [31] 2005 122 291 413 19 52 51 35 136 120 Case-control
Levesque [32] 2004 174 306 480 50 92 32 97 151 58 Nested case-contol
Mingwei [33] 1998 35 25 60 23 7 5 2 10 13 Case-control
Morgan [34] 1999 73 83 156 23 31 19 25 36 22 Case-control
Mozgovaia [35] 2000 45 73 118 21 14 10 28 37 8 Case-control
Roberts [36] 2004 391 338 729 183 164 44 152 142 44 Case-control
Roh [37] 1997 36 115 151 4 11 21 14 62 39 Case-control
Seremak-Mrozikiewicz [38] 2000 25 110 135 16 7 2 34 61 15 Case-control
Serrano et al.
(present study)
2006 665 1046 1711 140 382 143 230 607 209 Case-control
Tamura [39] 1996 12 179 191 3 6 3 63 82 34 Cohort
Wang [40] 2004 99 54 153 42 37 20 14 16 24 Case-control
Watanabe [41] 2001 96 96 192 13 48 35 10 40 46 Case-control
Zhou [42] 1999 60 78 138 39 12 9 8 32 38 Case-control
aStudies on which the reporting of the criteria to define preeclampsia was unclear. Results from these studies were compared against the others in Figure 3.
bDefinition used from a posterior manuscript from the same authors.
BP, blood pressure; HWE, Hardy-Weinberg equilibrium.
doi:10.1371/journal.pmed.0030520.t003
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Table 3. Extended.
Reference Source of
Controls
Matching
Variable
Systolic BP
Threshold
(mm Hg)
Diastolic BP
Threshold
(mm Hg)
Proteinuria
Threshold
Bai [22] Normal pregnant women Maternal age 140 90 Not specified
Bouba [23] Normotensive pregnant women
who had undergone at least two
pregnancies with no history of
preeclampsia
None 140 90 .300 mg/l in a random
specimen or an excretion
of .300 mg per 24 h
after 20 wk of gestation.
Choi H [24] Normotensive volunteers randomly recruited
from the Obstetric Service at the Samsung
Cheil Hospital
Maternal age 140 90 . 1 g/l (or 2þ dipstick)
in random urine
Dizon-Townson [25] Referred to only as ‘‘controls’’ None 140 90 . 500 mg of protein in
24 h or a new 3 dipstick
without infectionb
Galao [26] Normotensive pregnancy under medical assistance None 140 90 . 300 mg/24 h
Gurdol [27] 50 participants were complication-free-pregnancies.
The remaining 39 women were normotensive with
 2 pregnancies unaffected by preeclampsia
None 140 90 . 300 mg/l in a 24-h
collection
Heiskanen [28] Women who delivered at Kuopio University Hospital None 140 90 . 300 mg of urinary
protein in 24 h
Kaur [29] Normotensive primigravidae who
were followed till delivery
Gestation and
maternal age
140 90 . 0.3 g/l
Kim [30] Randomly selected nulliparous and parous women
who were not affected by preeclampsia in the
pregnancy progressing to .20 weeks’ gestation
None 140 90 . 300 mg/24 h
Kobashi [31] Randomly selected from healthy pregnant women None 140 90 30 mg/dl (1þ on a
dipstick) or greater
Levesque [32] Normotensive nulliparous women attending a
tertiary perinatal center
Maternal age,
gestational age,
body mass index,
and month of the
year at delivery.
Not
specified
90  0.3 g/l in a 24-h or
 1þ, using Albustix
Mingwei [33] Control population None Not
specified
Not
specified
Not specified
Morgan [34] Normotensive women recruited during the second
half of the pregnancy
None 140 90 . 300 mg/l in 24 h
or  2þ on dipstick
in a random urine
sample
Mozgovaia [35] Pregnant women without obvious somatic pathology None 140 90  0.3 g/l in a 24 h
Roberts [36] Healthy pregnant normotensive participants who
had delivery normally beyond 37th week of gestation
None 140 90 1þ on dipstick after
34 wk of gestation
Roh [37] Normal population None 140 90 . 300 mg/24 h
Seremak-Mrozikiewicz [38] Healthy pregnant women None 160 110 . 5 g in 24 h
Serrano et al.
(present study)
Healthy normotensive pregnant women at delivery
from the same hospitals where cases were recruited
None 140 90 . 0.3 g in 24 h, or
. 2þ reading on
dipstick in a random
sample
Tamura [39] Pregnant women enrolled in a clinical trial who did
not develop preeclampsia or pregnancy induced hypertension
None 140 90 Referred to as
proteinuria (not
threshold reported)
Wang [40] Normal pregnant women None Not
specified
Not
specified
Not specified
Watanabe [41] Healthy pregnant volunteers Maternal age 160 110  5 g in a 24-h collection
or  3þ on dipstick
testing of two random
urine samples collected
at least 4 h apart
Zhou [42] Healthy pregnant women None Not
specified
Not
specified
Not specified
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Table 3. Extended.
Reference Reference Cited to
Define Preeclampsia
Main Exclusion Criteria Country Ethnicity
Bai [22] Authors referred only to:
‘‘rigorous definition
of pre-eclampsia’’a
Not specified China Asian
Bouba [23] Not specified Preexisting cardiovascular or renal disease Greece European
Choi H [24] [66] Cardiac disease, serum creatinine
. 150 lmol/l or the presence of
other systemic disease
Korea Asian
Dizon-Townson [25] Not specifieda Not specified United States European
Galao [26] [66] History of essential or secondary
hypertension, multiparous women,
diabetes mellitus, renal disease
Brazil Hispanic
(European and
American Indian)
Gurdol [27] Not specified Preexisting hypertension Turkey European
Heiskanen [28] [67] Chronic hypertension and multiple pregnancy Finland European
Kaur [29] [66] Chronic hypertension, diabetes mellitus,
hyperthyroidism, sarcoidosis, chronic
renal disorders, collagen disorders
India South Asian
Kim [30] [66] No chronic hypertension. No personal or
family history of preeclampsia
(only for controls)
Korea Asian
Kobashi [31] [68] Preexisting hypertension, renal disease,
diabetes mellitus, amniotic fluid
abnormalities, fetal anomalies,
multiple pregnancies
Japan Asian
Levesque [32] [69] Preexisting secondary hypertension, preexisting
hypertension with superimposed preeclampsia,
multiple pregnancies
Canada European
Mingwei [33] Reported as standard criteria.
The authors cited a Chinese
textbook of obstetrics and
gynecology.a
Not specified China Asian
Morgan [34] Not specified History of essential hypertension, diabetes
mellitus, or chronic renal disease
United Kingdom European
Mozgovaia [35] Not specified Not specified Russia European
Roberts [36] Not specified History of hypertension in a previous pregnancy
(only for controls)
South Africa Afro-Caribbean
Roh [37] American College of
Obstetrics and Gynecology
Not specified Korea Asian
Seremak-Mrozikiewicz [38] Not specified Multiparous women Poland European
Serrano et al.
(present study)
[67] See methods section, manuscript Colombia Mixed (European, Hispanic,
Afro-Caribbean, and
Native American)
Tamura [39] Not specified Hypertension, renal disease, diabetes, or
other significant medical complications,
such as heart disease
United States Afro-Caribbean
Wang [40] Not specified  Not specified China Asian
Watanabe [41] [71] History of hypertension or renal disease Japan Asian
Zhou [42] Reported as standard criteria.
The authors cited a Chinese
textbook of obstetrics and
gynaecology
Not specified China Asian
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Proteus phenomenon [51]. Further evidence in support of the
presence of within-study reporting bias is the fact that studies
published in languages other than English, and in the Asian
ethnic group, tend to have larger effects, ﬁndings consistent
with other recent results [52].
Publication bias is increasingly being recognized as one of
the main threats to the reliability of conclusions drawn from
association studies with common disease outcomes. In the
setting of cardiovascular and neurological diseases, several
positive gene–disease associations, usually based on meta-
analysis of small studies, have been subsequently refuted by
large genetic studies [13,53]. As a result, several initiatives are
Figure 2. Meta-Analysis of Studies of ACE-I/D Polymorphism and Risk of Preeclampsia
doi:10.1371/journal.pmed.0030520.g002
Figure 3. Studies of ACE-I/D Polymorphism and Risk of Preeclampsia Grouped by Study Characteristics
doi:10.1371/journal.pmed.0030520.g003
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now underway to help overcome problems of reporting and
publication bias and to help to achieve datasets of appro-
priate size to detect plausible genetic effects for common
disorders, which are likely to require several thousands of
cases of the disease (The Wellcome Trust Case Control
Consortium, http://www.wtccc.org.uk) [54]. Genetic studies in
preeclampsia continue to be somewhat small in size [55,56]
and are usually underpowered to detect realistic genotypic
relative risks (ORs between 1.15 and 1.4) [14,57]. However,
considering the low incidence of preeclampsia (2%–3% in
developed countries), it is highly unlikely that a single centre
will be able to amass the large number of cases required, and
the development of networks of interested investigators may
be essential [54]. Therefore, international collaborations,
particularly among those countries with a high incidence of
preeclampsia, may make recruitment more efﬁcient and help
to include participants with different cultural and genetic
backgrounds, which can provide further insight into the
aetiology of the disease both genetic and/or environmental.
Despite these obstacles, the investment in adequate
resources to study the genetics of preeclampsia is an
important priority. Observational studies and the rando-
mised trials of interventions that have followed have been
unsuccessful thus far in identifying causal pathways in
preeclampsia amenable to preventive therapies, a clear
example of which are the recently failed clinical trials using
either antioxidant vitamins or calcium supplements [58–61].
A genetic approach that is less prone to confounding and
reverse causation than nongenetic observational studies, may
be more likely to identify causal pathways and may help to
prioritise therapeutic targets that require evaluation in large
and expensive randomised clinical trials [62,63]. The chal-
lenge is in how to make better use of the genetic approach in
complex diseases such as preeclampsia, in particular to
overcome random errors in risk estimates from small studies
as well as publication bias. A suggested approach is to
establish a collaborating consortium of investigators from
existing studies in genetics of preeclampsia to reduce the
multiple existing problems such as: (1) inadequate selection
of candidate gene variants to be evaluated, (2) biased analyses,
and selective reporting of positive results; (3) to promote
access to unpublished data; (4) to overcome inadequate
outcome deﬁnitions; and (5) to provide guidance for
developing new large studies [54]. Until such measures are
established, it will be important for both authors and journal
editors to embrace the publication of both positive and
negative results from ‘‘well-designed case-control’’ studies to
diminish the problem of publication bias [64]. This approach
has recently become a reality for clinical trials [65], and it
might help in reducing the temptation of researchers to
explore multiple hypotheses in subgroup analyses to obtain
one ﬁnding of nominal statistical signiﬁcance that might help
acceptance of the paper.
Investigating the aetiology of preeclampsia, one of the
main causes of maternal and neonatal mortality and morbid-
ity worldwide, should be a health research priority. A genetic
approach may indeed be useful, but large collaborative
studies will also be needed.
Supporting Information
Figure S1. Funnel Plot of Studies of ACE-I/D Polymorphism and
Preeclampsia
ORs for outcome using a per-allele model. Studies in bold are those
published in non-English-language journals.
Found at doi:10.1371/journal.pmed.0030520.sg001 (38 KB PPT).
Figure S2. Cumulative Synthesis of Studies of ACE-I/D Polymorphism
and Preeclampsia
OR (random effect model) for outcome using a per-allele model.
Found at doi:10.1371/journal.pmed.0030520.sg002 (36 KB PPT).
Protocol S1. ACE-I/D Polymorphism and Preeclampsia Risk: Evidence
of Small-Study Bias
Found at doi:10.1371/journal.pmed.0030520.sd001 (68 KB DOC).
Alternative Language Abstract S1. Translation of the Abstract into
Spanish
Translation by N. C. Serrano, Universidad Auto´noma de Bucara-
manga, Bucaramanga, Colombia.
Found at doi:10.1371/journal.pmed.0030520.sd002 (25 KB DOC).
Alternative Language Abstract S2. Translation of the Abstract into
Chinese
Translation by D. Wang, Medical Statistics Unit, London School of
Hygiene and Tropical Medicine, London, United Kingdom.
Found at doi:10.1371/journal.pmed.0030520.sd003 (33 KB DOC).
Table 5. Genotypic ORs for Preeclampsia and the ACE-I/D Variant.
Model Comparison ACE-I/D Variant
Additive model Random, OR (95% CI), p-value 1.26 (1.07–1.49), p ¼ 0.006
I2 (p for heterogeneity) 75.1% (p , 0.0001)
Egger test, p-value p ¼ 0.06
Homozygous for rare allele versus homozygous for common allele Random, OR (95% CI), p-value 1.51 (1.09–2.08), p ¼ 0.01
I2 (p for heterogeneity) 71.8% (p , 0.0001)
Egger test, p-value p ¼ 0.02
Heterozygous versus homozygous for common allele Random, OR (95% CI), p-value 0.94 (0.78–1.12), p ¼ 0.50
I2 (p for heterogeneity) 31.5% (p ¼ 0.07)
Egger test, p-value p ¼ 0.76
Recessive model Random, OR (95% CI), p-value 1.59 (1.22–2.07), p ¼ 0.001
I2 (p for heterogeneity) 74.5% (p , 0.0001)
Egger test, p-value p ¼0.008
Dominant model Random, OR (95% CI), p-value 1.15 (0.91–1.45), p ¼ 0.21
I2 (p for heterogeneity) 63.1% (p , 0.0001)
Egger test, p-value p ¼ 0.09
doi:10.1371/journal.pmed.0030520.t005
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Accession Numbers
The SNP database (http://www.ncbi.nlm.nih.gov/SNP/) single-nucleo-
tide polymorphism discussed in this paper is an insertion/deletion
variant (rs1799752) referenced to the ACE gene with the GenBank
(http://www.ncbi.nlm.nih.gov/Genbank/) accession number J04144.
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Editors’ Summary
Background. Preeclampsia is a common condition affecting pregnant
women worldwide; it is defined as the presence of increased blood
pressure, together with protein in the urine. Although in many women
preeclampsia may never result in symptoms, other women may
experience headaches, problems with their vision, swollen ankles and
feet, and other problems. Sometimes, preeclampsia progresses to
eclampsia, in which potentially life-threatening seizures result. The
causes of preeclampsia are not well understood, but several factors are
known to contribute to the risk. These factors include diabetes, high
blood pressure prior to pregnancy, obesity, and first pregnancy. There is
also the possibility that preeclampsia has, at least in part, a genetic basis;
the condition is more likely among women whose relatives have also had
it. However, no definite genetic cause has yet been confirmed.
Why Was This Study Done? A common variant in one particular gene,
ACE, which codes for the angiotensin-1 converting enzyme, has been
linked with preeclampsia in a number of different studies. The protein
encoded by ACE is involved in controlling blood pressure and the
balance of fluid and salts in the blood. However, many of the studies
supposedly linking ACE and preeclampsia were done on very few
participants. Small studies are more likely to generate ‘‘false positive’’
findings. Therefore, a group of investigators from Colombia and the UK
wanted to find out whether they could reproduce the supposed link
between the ACE gene variant and preeclampsia in a large study, and
also to see whether the previous studies could have been ‘‘false
positives.’’
What Did the Researchers Do and Find? These investigators carried
out a case-control study. This means that women with preeclampsia
(‘‘cases’’) were recruited, and compared with women similar in all other
respects but who did not have preeclampsia (‘‘controls’’). In total 1,711
pregnant women from five Colombian cities were studied, of whom 665
had preeclampsia and 1,046 did not. Blood was taken from each
participant and used for DNA sequencing of the ACE gene. The
investigators then did a statistical comparison to see whether there
was any association between preeclampsia and possession of a particular
variant of the ACE gene. The results showed that there was no such
association. Then, the investigators did a literature search to find all
previous studies that had examined a possible link between variants of
the ACE gene and preeclampsia. They found 22 studies reporting data
obtained from 6,424 women (these figures include the results from the
investigators’ own case-control study described here). The data from all
of these studies were then put together into a combined analysis. This
combined analysis did suggest a small increase in the risk of
preeclampsia in women with one particular variant in the ACE gene.
However, this result was more likely in studies with small numbers of
participants. Furthermore, the earliest studies done were most likely to
show an effect, with the supposed link disappearing as more and more
data were collected.
What Do These Findings Mean? The findings presented here suggest
that ‘‘small study bias’’ may explain the discrepancy between the results
of the case-control study and the combined analysis. That is, studies
involving few participants are less reliable and more likely to produce
false-positive results. Therefore, it is possible that the proposed link
between ACE gene variants and preeclampsia is a spurious one. The
investigators propose that in future, collaborative research networks will
be needed to carry out rigorous research on the genetics of
preeclampsia. Such initiatives will help to overcome the problem of
bias that can arise from small studies.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030520.
 Information for patients from NHS Direct (UK National Health Service)
about preeclampsia
 Medical encyclopedia entry on preeclampsia from MedLine Plus,
supplied by the US National Library of Medicine
 Information from the World Health Organization and Pan American
Health Organization on maternal health in the Americas
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